CRMD NASDAQ
Credit Risk of going bust: higher than 65% of companies Debt: 18.9% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.22 (down 97%), CorMedix Inc. would be worth roughly what it owes.
Total debt $145.2M against a stock market value of $623.6M.
Distance to default 3.84 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $72.6M (short-term plus half of long-term), stock volatility 62.0%; Altman Z'' 4.41. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Parsippany, NJ 07054
US
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Dillione Janet | M-Exempt | 48,909 | — | 2026-09-18 |
| Dillione Janet | M-Exempt | 48,909 | — | 2026-09-18 |
| Blum Susan | F-InKind | 8,424 | $8.30 | 2026-08-29 |
| Hurlburt Elizabeth | F-InKind | 8,076 | $8.30 | 2026-08-29 |
| Zelnick Kaufman Beth | F-InKind | 8,424 | $8.30 | 2026-08-29 |